

## Technology Transfer for Manufacturing of COVID-19 Recombinant Protein-based Vaccine to Vietnam

---

**OSAKA, Japan, July, 28, 2021** - Shionogi & Co., Ltd. (hereafter "Shionogi") announced that Shionogi is in discussions with the Socialist Republic of Vietnam (hereinafter "Vietnam") regarding technology transfer for the manufacturing of the COVID-19 recombinant protein-based vaccine that we are developing in Japan.

Shionogi recognizes Japan's global role in addressing this pandemic by contributing to effective countermeasures worldwide, which is fully aligned with our own mission as a company dedicated to the control of infectious diseases. Therefore, we are proceeding with discussions regarding this technology transfer to Vietnam. Yesterday, it was reported that an agreement had already been concluded in this regard between Shionogi and a Vietnamese company, but it is still under discussion and a final detailed agreement has not yet been reached.

This matter does not affect Shionogi's vaccine development and production planning in Japan.

### **Forward-Looking Statements**

*This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.*

### **For Further Information, Contact:**

SHIONOGI Website Inquiry Form : <https://www.shionogi.com/global/en/contact.html>